




PHARMACEUTICAL 2023

Sio Gene Therapies Inc.
Rank 237 of 446





PHARMACEUTICAL 2023

Sio Gene Therapies Inc.
Rank 237 of 446



The relative strengths and weaknesses of Sio Gene Therapies Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sio Gene Therapies Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 69% points. The greatest weakness of Sio Gene Therapies Inc. is the variable Net Income, reducing the Economic Capital Ratio by 79% points.

The company's Economic Capital Ratio, given in the ranking table, is 71%, being 28% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	71,736
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	13,002
Liabilities, Non-Current	1,730
Other Assets	2,444
Other Compr. Net Income	2.0
Other Expenses	286
Other Liabilities	0
Other Net Income	-39
Other Revenues	0
Property and Equipment	900
Research and Development	53,399
Selling, General and Administrative Expense	18,163

Output Variable	Value in 1000 USD
Assets	75,080
Liabilities	14,732
Expenses	71,848
Revenues	0
Stockholders Equity	60,348
Net Income	-71,887
Comprehensive Net Income	-71,886
Economic Capital Ratio	71%